James P Conway

5PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 12, 2025
Targeting α v β 8 Integrin with mAb MEDI8367 Prevents Fibrosis in Preclinical Models of CKD.

Elena Liarte Marin, Asha Seth, Lihuan Liang

|Dec 08, 2025
T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.

Robin K Kelley, Young Lee, James Conway

|Feb 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park

|Oct 28, 2021
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.

Christian T Ruff, Michael J Koren, Joseph Grimsby

|Sep 23, 2020
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma.

Elena Pontarini, William James Murray-Brown, Cristina Croia

Pageof 1

Frequent Collaborators

1 joint publications

Elena Pontarini

1 joint publications

William James Murray-Brown

1 joint publications

Cristina Croia

1 joint publications

Davide Lucchesi